Evidence that Differences in Fructosamine-3-Kinase Activity May be Associated with the Glycation Gap in Human Diabetes

Simon J Dunmore, Amr S Al-Derawi, Ananth U Nayak, Aruna Narshi, Alan M Nevill, Anne Hellwig, Andrew Majebi, Paul Kirkham, James E Brown, Baldev M Singh

Research output: Contribution to journalArticle

Abstract

The phenomenon of a discrepancy between glycated haemoglobin levels and other indicators of average glycaemia may be due to many factors but can be measured as the glycation gap (GGap). This GGap is associated with differences in complications in patients with diabetes and may possibly be explained by dissimilarities in deglycation in turn leading to altered production of Advanced Glycation End (AGE) products. We hypothesised that variations in the level of the deglycating enzyme Fructosamine-3-kinase (FN3K) might be associated with the GGap. We measured erythrocyte FN3K concentrations and enzyme activity in a population dichotomised for a large positive or negative GGap. FN3K protein was higher and we found a striking 3-fold greater activity (323%) at any given FN3K protein level in the erythrocytes of the negative compared with positive GGap groups. This was associated with lower AGE levels in the negative GGap group (79%), lower pro-inflammatory adipokines (Leptin/Adiponectin ratio) (73%) and much lower pro-thrombotic PAI-1 levels (19%). We conclude that FN3K may play a key role in the GGap and thus diabetes complications such that FN3K may be potential predictor of the risk of diabetes complications. Pharmacological modifications of its activity may provide a novel approach to their prevention.

Original languageEnglish
JournalDiabetes
Volume67
Issue number1
Early online date24 Oct 2017
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint

Diabetes Complications
Erythrocytes
Advanced Glycosylation End Products
Adipokines
Adiponectin
Plasminogen Activator Inhibitor 1
Glycosylated Hemoglobin A
Enzymes
Leptin
fructosamine-3-kinase
Proteins
Pharmacology
Population

Bibliographical note

© 2017 by the American Diabetes Association.

Funding: Wolverhampton Diabetes Trust.

Cite this

Dunmore, S. J., Al-Derawi, A. S., Nayak, A. U., Narshi, A., Nevill, A. M., Hellwig, A., ... Singh, B. M. (2018). Evidence that Differences in Fructosamine-3-Kinase Activity May be Associated with the Glycation Gap in Human Diabetes. Diabetes, 67(1). https://doi.org/10.2337/db17-0441
Dunmore, Simon J ; Al-Derawi, Amr S ; Nayak, Ananth U ; Narshi, Aruna ; Nevill, Alan M ; Hellwig, Anne ; Majebi, Andrew ; Kirkham, Paul ; Brown, James E ; Singh, Baldev M. / Evidence that Differences in Fructosamine-3-Kinase Activity May be Associated with the Glycation Gap in Human Diabetes. In: Diabetes. 2018 ; Vol. 67, No. 1.
@article{50cf662b0e424f08863cae9431681451,
title = "Evidence that Differences in Fructosamine-3-Kinase Activity May be Associated with the Glycation Gap in Human Diabetes",
abstract = "The phenomenon of a discrepancy between glycated haemoglobin levels and other indicators of average glycaemia may be due to many factors but can be measured as the glycation gap (GGap). This GGap is associated with differences in complications in patients with diabetes and may possibly be explained by dissimilarities in deglycation in turn leading to altered production of Advanced Glycation End (AGE) products. We hypothesised that variations in the level of the deglycating enzyme Fructosamine-3-kinase (FN3K) might be associated with the GGap. We measured erythrocyte FN3K concentrations and enzyme activity in a population dichotomised for a large positive or negative GGap. FN3K protein was higher and we found a striking 3-fold greater activity (323{\%}) at any given FN3K protein level in the erythrocytes of the negative compared with positive GGap groups. This was associated with lower AGE levels in the negative GGap group (79{\%}), lower pro-inflammatory adipokines (Leptin/Adiponectin ratio) (73{\%}) and much lower pro-thrombotic PAI-1 levels (19{\%}). We conclude that FN3K may play a key role in the GGap and thus diabetes complications such that FN3K may be potential predictor of the risk of diabetes complications. Pharmacological modifications of its activity may provide a novel approach to their prevention.",
author = "Dunmore, {Simon J} and Al-Derawi, {Amr S} and Nayak, {Ananth U} and Aruna Narshi and Nevill, {Alan M} and Anne Hellwig and Andrew Majebi and Paul Kirkham and Brown, {James E} and Singh, {Baldev M}",
note = "{\circledC} 2017 by the American Diabetes Association. Funding: Wolverhampton Diabetes Trust.",
year = "2018",
month = "1",
day = "1",
doi = "10.2337/db17-0441",
language = "English",
volume = "67",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association Inc.",
number = "1",

}

Dunmore, SJ, Al-Derawi, AS, Nayak, AU, Narshi, A, Nevill, AM, Hellwig, A, Majebi, A, Kirkham, P, Brown, JE & Singh, BM 2018, 'Evidence that Differences in Fructosamine-3-Kinase Activity May be Associated with the Glycation Gap in Human Diabetes', Diabetes, vol. 67, no. 1. https://doi.org/10.2337/db17-0441

Evidence that Differences in Fructosamine-3-Kinase Activity May be Associated with the Glycation Gap in Human Diabetes. / Dunmore, Simon J; Al-Derawi, Amr S; Nayak, Ananth U; Narshi, Aruna; Nevill, Alan M; Hellwig, Anne; Majebi, Andrew; Kirkham, Paul; Brown, James E; Singh, Baldev M.

In: Diabetes, Vol. 67, No. 1, 01.01.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evidence that Differences in Fructosamine-3-Kinase Activity May be Associated with the Glycation Gap in Human Diabetes

AU - Dunmore, Simon J

AU - Al-Derawi, Amr S

AU - Nayak, Ananth U

AU - Narshi, Aruna

AU - Nevill, Alan M

AU - Hellwig, Anne

AU - Majebi, Andrew

AU - Kirkham, Paul

AU - Brown, James E

AU - Singh, Baldev M

N1 - © 2017 by the American Diabetes Association. Funding: Wolverhampton Diabetes Trust.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The phenomenon of a discrepancy between glycated haemoglobin levels and other indicators of average glycaemia may be due to many factors but can be measured as the glycation gap (GGap). This GGap is associated with differences in complications in patients with diabetes and may possibly be explained by dissimilarities in deglycation in turn leading to altered production of Advanced Glycation End (AGE) products. We hypothesised that variations in the level of the deglycating enzyme Fructosamine-3-kinase (FN3K) might be associated with the GGap. We measured erythrocyte FN3K concentrations and enzyme activity in a population dichotomised for a large positive or negative GGap. FN3K protein was higher and we found a striking 3-fold greater activity (323%) at any given FN3K protein level in the erythrocytes of the negative compared with positive GGap groups. This was associated with lower AGE levels in the negative GGap group (79%), lower pro-inflammatory adipokines (Leptin/Adiponectin ratio) (73%) and much lower pro-thrombotic PAI-1 levels (19%). We conclude that FN3K may play a key role in the GGap and thus diabetes complications such that FN3K may be potential predictor of the risk of diabetes complications. Pharmacological modifications of its activity may provide a novel approach to their prevention.

AB - The phenomenon of a discrepancy between glycated haemoglobin levels and other indicators of average glycaemia may be due to many factors but can be measured as the glycation gap (GGap). This GGap is associated with differences in complications in patients with diabetes and may possibly be explained by dissimilarities in deglycation in turn leading to altered production of Advanced Glycation End (AGE) products. We hypothesised that variations in the level of the deglycating enzyme Fructosamine-3-kinase (FN3K) might be associated with the GGap. We measured erythrocyte FN3K concentrations and enzyme activity in a population dichotomised for a large positive or negative GGap. FN3K protein was higher and we found a striking 3-fold greater activity (323%) at any given FN3K protein level in the erythrocytes of the negative compared with positive GGap groups. This was associated with lower AGE levels in the negative GGap group (79%), lower pro-inflammatory adipokines (Leptin/Adiponectin ratio) (73%) and much lower pro-thrombotic PAI-1 levels (19%). We conclude that FN3K may play a key role in the GGap and thus diabetes complications such that FN3K may be potential predictor of the risk of diabetes complications. Pharmacological modifications of its activity may provide a novel approach to their prevention.

UR - https://www.scopus.com/record/display.uri?eid=2-s2.0-85038889685&origin=SingleRecordEmailAlert&dgcid=raven_sc_affil_en_us_email&txGid=16d28e49321ec16ec63fadee626bb85f

U2 - 10.2337/db17-0441

DO - 10.2337/db17-0441

M3 - Article

C2 - 29066600

VL - 67

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 1

ER -